Early Tight Blood Glucose Control Reduces Eye Surgeries in People with Type 1 Diabetes
People with type 1 diabetes who intensively control their blood glucose (blood sugar) early in their disease, versus those who do not, are 48 percent less likely to need eye surgery, and the total number of such surgeries is 37 percent less. (Source: News from NEI)
Source: News from NEI - May 8, 2015 Category: Opthalmology Authors: Jason Source Type: news
NIH-funded Study Points Way Forward for Retinal Disease Gene Therapy
Gene therapy for Leber congenital amaurosis (LCA), an inherited disorder that causes vision loss starting in childhood, improved patients’ eyesight and the sensitivity of the retina within weeks of treatment. Both of these benefits, however, peaked one to three years after treatment and then diminished, according to results from an ongoing clinical trial funded by the National Eye Institute (NEI), part of the National Institutes of Health.
Language
English (Source: News from NEI)
Source: News from NEI - May 1, 2015 Category: Opthalmology Authors: Jason Source Type: news
NIH Launches Research to Gaze Deeply Into Your Eyes
Five bold projects will develop new technology to noninvasively image cells of the eye in unprecedented detail. The National Eye Institute (NEI) announced the awards as part of its Audacious Goals Initiative. NEI has committed $3.8 million to the projects in 2015 and up to $17.9 million over the next five years, pending the availability of funds. NEI is part of the National Institutes of Health.
Language
English (Source: News from NEI)
Source: News from NEI - April 30, 2015 Category: Opthalmology Authors: Jason Source Type: news
NEI Human Gene Therapy Trial for Retinoschisis Underway
The National Eye Institute (NEI) recently launched the first-ever human gene therapy trial for the vision disorder X-linked retinoschisis (XLRS). Researchers are conducting the trial at the National Institutes of Health Clinical Research Center in Bethesda, Maryland. (Source: News from NEI)
Source: News from NEI - March 13, 2015 Category: Opthalmology Authors: David Source Type: news
Brain Training May Bolster Visual Attention
People are bad at staying focused. We’ve all had our minds wander when we try to concentrate on a task that requires paying close attention but isn’t all that engaging. But a new NIH-funded study suggests that one’s capacity to stay focused can improve with real-time feedback.
“The reason we are bad at staying focused is because we are bad at monitoring our attentional state,” explained Nicholas Turk-Browne, Ph.D., associate professor in the Department of Psychology at Princeton University. Dr. Turk-Browne’s lab led the study published in Nature Neuroscience. (Source: News from NEI)
Source: News from NEI - February 18, 2015 Category: Opthalmology Authors: Jason Source Type: news
Eylea outperforms other drugs for diabetic macular edema with moderate or worse vision loss
In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse at the start of the trial. However, the three drugs resulted in similar average improvement when starting vision was 20/40 to 20/32. Investigators found no major differences in the safety of the three drugs. The trial was funded by the National Eye Institute (NEI), part of the National Institutes of Health.
Language
English (Source: News from NEI)
Source: News from NEI - February 16, 2015 Category: Opthalmology Authors: Jason Source Type: news
HIV drugs show promise for “dry” AMD
A class of medications long used to curb HIV infection shows promise as a therapy for age-related macular degeneration (AMD), suggest findings from an NIH-funded study. These mainstay HIV drugs, called nucleoside reverse transcriptase inhibitors (NRTIs), may eventually be repurposed to treat a host of other inflammatory disorders, too. (Source: News from NEI)
Source: News from NEI - December 22, 2014 Category: Opthalmology Authors: Noemi Source Type: news
Glaucoma: The 'silent thief' begins to tell its secrets
Glaucoma is sometimes called the "silent thief of sight" because it slowly damages the eyes and can cause irreparable harm before there is any vision loss. But this disease is stealthy in more ways than one. Glaucoma has been known at least since antiquity, and yet, researchers today still do not know what causes it in most cases. There are treatments to delay vision loss, but no cure, making it a leading cause of blindness all over the world. (Source: News from NEI)
Source: News from NEI - October 28, 2014 Category: Opthalmology Source Type: news
